No Data
No Data
Genmab's Strong Earnings Call Highlights Growth and Optimism
Genmab A/S (GMAB) Q4 2024 Earnings Conference Call Transcript Summary
A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $27 to $50
Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today
Genmab Shares Are Trading Higher After the Company Issued a Year-over-year Increase for Its FY25 Revenue Guidance. Also, Leerink Partners Upgraded the Stock From Market Perform to Outperform and Announced a Price Target of $27.
Analysts Have Conflicting Sentiments on These Healthcare Companies: Corbus Pharmaceuticals (CRBP), Genmab (GMAB) and CVRx (CVRX)